The anti-tumor necrosis factor alpha (anti-TNF-α) agents infliximab and adalimumab are effective biologic treatments used to treat people with moderate-to-severe IBD [4,5], as well as populations defined as at ‘high-risk’ for disease complications [6]. The gene discussed is TNF; the disease is inflammatory bowel disease.